Skip to main content
Evaxion A/S logo

Evaxion A/S — Investor Relations & Filings

Ticker · EVAX ISIN · US29970R3030 US Professional, scientific and technical activities
Open in API
Filings indexed 327 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country US United States of America
Listing US EVAX

About Evaxion A/S

https://evaxion.ai/

Evaxion A/S is a clinical-stage TechBio company specializing in the development of immunotherapies using its proprietary, clinically validated AI-Immunology™ platform. The platform leverages artificial intelligence and machine learning to decode the human immune system, enabling the rapid discovery and design of novel vaccine targets. Evaxion focuses on creating personalized and precision vaccines for the treatment of cancer and infectious diseases. Its pipeline includes personalized cancer vaccines in clinical development, such as EVX-01 for melanoma, and a preclinical portfolio targeting infectious diseases. The company's technology aims to accelerate the development of tailored vaccine candidates to address critical diseases.

Recent filings

Filing Released Lang Actions
6-K - Evaxion A/S (0001828253) (Filer)
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 6-K, which foreign private issuers use to furnish material information (in this case, a press release) under the Exchange Act. It does not contain substantive financial statements or constitute an annual/quarterly report, nor is it a notice of a forthcoming report — it is itself a regulatory filing of a press release. Therefore it falls under the catch-all category of Regulatory Filings (RNS).
2026-05-12 English
6-K - Evaxion A/S (0001828253) (Filer)
Regulatory Filings Classification · 90% confidence The document is a Form 6-K SEC submission by a foreign private issuer (Evaxion A/S) furnishing a press release and first quarter results as an exhibit. It does not itself contain full financial statements nor is it limited to an earnings summary; rather it serves as a regulatory filing under the Exchange Act to furnish the press release. Therefore it falls under the general “Regulatory Filings” category (RNS).
2026-05-07 English
6-K - Evaxion A/S (0001828253) (Filer)
Regulatory Filings Classification · 90% confidence The document is a Form 6-K submission by a foreign private issuer (Evaxion A/S) to the SEC, primarily furnishing a press release regarding an upcoming business update and Q1 2026 financial results. It does not contain actual financial results or statements, nor is it the full report itself, but rather a regulatory notice under the Securities Exchange Act. This fits the fallback category for general regulatory announcements (Form 6-K) rather than an earnings release or annual/interim report.
2026-05-04 English
6-K - Evaxion A/S (0001828253) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a management promotion (Birgitte Rønø promoted to joint Chief Scientific and Chief Operating Officer). The document does not contain financial statements or detailed financial data, nor does it announce voting results, dividends, or capital changes. It is primarily an announcement of a management change. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3416 characters, which is relatively short and consistent with an announcement rather than a full report.
2026-04-27 English
6-K - Evaxion A/S (0001828253) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Evaxion A/S, reporting on resolutions passed at the Annual General Meeting held on April 16, 2026. It includes detailed voting results on agenda items such as election of board members, approval of the audited annual report, authorization for issuance of warrants and convertible loan notes, and amendments to the articles of association. The content focuses on the official results of shareholder votes and related corporate governance decisions made at the AGM. There is no full annual report or financial statements included, but rather the formal announcement of voting outcomes and resolutions passed at the AGM. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" which covers official results from shareholder votes at any general meeting. The document length (9877 characters) and detailed voting results further support this classification rather than a brief announcement or a full report.
2026-04-22 English
6-K - Evaxion A/S (0001828253) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Evaxion A/S, submitted to the SEC. It includes a press release about the company's AI-Immunology platform results in a phase 2 trial. The document is relatively short (3472 characters) and primarily serves to furnish a press release as an exhibit. There are no financial statements, detailed financial data, or comprehensive reports included. The document is an announcement of information rather than the report itself. According to the rules, such filings that provide press releases or updates without substantive financial data or full reports are best classified as Regulatory Filings (RNS).
2026-04-17 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.